 |
gutin-webcast Posted by: mskcc
Video duration: 1514 seconds gutin-webcast |
 |
segment 6-CS 20111011 Kidney-H.264 960x540 Posted by: mskcc
Video duration: 1446 seconds segment 6-CS 20111011 Kidney-H.264 960x540 |
 |
Head and Neck Cancer Q&A Posted by: mskcc
Video duration: 1319 seconds Experts from Memorial Sloan-Kettering answer questions about advances in the treatment of head and neck tumors. |
 |
Introduction to Head and Neck Cancer Posted by: mskcc
Video duration: 1084 seconds Many head and neck cancers can be cured, but getting the best outcome requires close cooperation among a variety of medical specialists. |
 |
Radiation Therapy and Safety Posted by: mskcc
Video duration: 808 seconds Highly precise radiation therapy techniques offer effective, localized treatment for many head and neck cancer patients. |
 |
Reconstructive Surgery for Head and Neck Cancer Posted by: mskcc
Video duration: 403 seconds New techniques in plastic and reconstructive surgery can help restore patients' appearance and function after surgery for head and neck cancer. |
 |
Diagnosing Head and Neck Cancer Posted by: mskcc
Video duration: 437 seconds Head and neck tumors are among the easiest cancers to detect and are more treatable when found early, say MSKCC experts. |
 |
Surgery for Head and Neck Cancer -- Sloan-Kettering Posted by: mskcc
Video duration: 384 seconds Head and neck surgeons at Memorial Sloan-Kettering Cancer Center discuss minimally invasive approaches to removing tumors. |
 |
Rehabilitation after Head and Neck Cancer Treatment -- Sloan-Kettering Posted by: mskcc
Video duration: 212 seconds Physicians discuss the role of rehabilitation therapy for patients after treatment for head and neck cancer. |
 |
Getting in Shape: New Clues from the Fly Embryo -- Sloan-Kettering Posted by: mskcc
Video duration: 1986 seconds Developmental biologist Jennifer Zallen discusses the use of live imaging to understand how embryos form their shape during development. In particular, cells in developing Drosophila (fruit fly) embryos are rearranged through the formation of groups of multicellular structures called rosettes. |
![Chromatin: Its Role, Its Relationship to Cancer, and How It\](http://img.youtube.com/vi/WzHxWQsHejA&feature=youtube_gdata/2.jpg "Chromatin: Its Role, Its Relationship to Cancer, and How It\") |
Chromatin: Its Role, Its Relationship to Cancer, and How It's Inherited -- Sloan-Kettering Posted by: mskcc
Video duration: 2287 seconds Molecular Biologist Iestyn Whitehouse discusses how the structure of chromatin -- a combination of DNA and proteins in a cell's nucleus -- is used to regulate fundamental biological processes. |
 |
MicroRNAs in Development and Cancer: A Tale of Mice and Men -- Sloan-Kettering Posted by: mskcc
Video duration: 2145 seconds Cancer biologist Andrea Ventura explains how his lab uses genetically engineered mouse models to understand how cancer works, why we get cancer, and how his research helps discover new targets for cancer therapy. |
 |
Major Trends in Modern Cancer Research 2011: Opening Remarks -- Sloan-Kettering Posted by: mskcc
Video duration: 268 seconds Memorial Sloan-Kettering President and CEO Craig Thompson welcomes attendees to the sixth annual Major Trends in Modern Cancer Research lecture and introduces the speakers. |
 |
Developing New Treatments for T Cell Lymphoma Posted by: mskcc
Video duration: 270 seconds Medical oncologist Steven M. Horwitz discusses the development and impact of three new, widely used therapies for T cell lymphoma. |
 |
Live from ASH 2011: Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225-Lintuzu Posted by: mskcc
Video duration: 78 seconds Medical oncologist Joseph Jurcic discusses a dose-escalation trial reviewing the safety, pharmacology, and biological activity of 225Ac-lintuzumab in AML. |
 |
Live From ASH 2011: Late Relapses following ATRA for APL Are Uncommon, Respond Well to Salvage Thera Posted by: mskcc
Video duration: 93 seconds Leader of the Acute Lymphoblastic Leukemia Program Dan Douer discusses a study examining late relapses among APL patients. |
 |
Live from ASH 2011: Older Age and Co-Morbidities Do Not Predict Incidence of Dose Limiting Toxiciti Posted by: mskcc
Video duration: 86 seconds Clinical Director of the Lymphoma Outpatient Unit Paul Hamlin discusses relationship between DLT and SAE with increasing age and comorbidities in lymphoma trials. |
 |
Live from ASH 2011: Validation of a Prognostic Model and the Impact of SF3B1, DNMT3A, and Other Muta Posted by: mskcc
Video duration: 74 seconds Medical oncologist Omar Abdel-Wahab discusses a study that validates a lower-risk prognostic scoring system's ability to identify higher-risk MDS patients. |
 |
Live from ASH 2011: Patterns of Disease Relapse and Progression in Patients with Multiple Myeloma af Posted by: mskcc
Video duration: 109 seconds Medical oncologist Hani Hassoun reviews a study that examined patterns of post-ASCT relapse. |
 |
Live from ASH 2011: A phase II Study of Ofatumumab in Combination with ICE or DHAP chemotherapy in r Posted by: mskcc
Video duration: 110 seconds Medical oncologist Matthew Matasar discusses the inclusion of OFA in second-line therapy for aggressive or relapsing B-cell non-Hodgkin's lymphoma. |
